Regulatory Momentum Vivasure has European CE mark approval for PerQseal Elite and is pursuing U.S. IDE PATCH Pivotal study results, signaling regulatory progress and near-term market entry opportunities in Europe and the United States for large-bore vascular closure devices.

Strategic Investor Backing Strong funding and backing from Haemonetics and international VC/state agencies suggest validated demand and potential co-marketing or channel leverage, enabling accelerated access to larger hospital networks and broader adoption.

Absorbable Technology Unique fully absorbable, patch-based closure technology targets large-bore arteriotomies with a sutureless approach, presenting a differentiated value proposition for interventional centers seeking reduced long-term device retention and improved patient recovery.

Expansion Opportunities Active development of PerQseal Blue for venous vessel closure expands addressable procedure types (TMVR, TTVR) and potentially new clinical pathways, opening cross-sell opportunities within existing cardiovascular programs.

Clinical Validation Positive early results from the PATCH pivotal study and ongoing trials create talking points for clinical endorsements, payer discussions, and hospital adoption strategies to drive procurement conversations.